neuroClues raises €10M Series A for AI-powered neurological biomarkers
Summary
neuroClues raised €10 million in Series A funding led by Teampact Ventures, White Fund, and the EIC Fund, with participation from existing investors including InvestBW, Leansquare, and Wallonie Entreprendre. The French-Belgian medtech company has developed a portable, CE-marked Class IIa medical device that extracts neurological biomarkers from eye movements to enable early detection of Parkinson's Disease, Alzheimer's, and Multiple Sclerosis.
Why it matters
neuroClues is replacing the subjective 'follow my finger' neurological exam with quantifiable, AI-powered ocular biomarkers that can detect neurological disorders years before visible symptoms appear. With CE certification obtained in January 2025 and deployment across 7 European countries, this funding accelerates European commercial rollout and prepares the company for FDA submission and US market entry.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial